HIV Cancer Care Integration in Sub-Saharan Africa

By Crystal Lubbe

January 28, 2025

How can integrating HIV care transform cancer treatment in Africa? A recent published article explores the perspectives of healthcare providers on integrating HIV cancer care integration into cancer centers in Malawi, South Africa, Uganda, and Zimbabwe. While oncology care providers express concerns about managing patients who have both cancer and HIV, they generally maintain a positive attitude toward HIV cancer care integration. Nonetheless, several barriers, including workspace limitations, workflow disruptions, staff availability, and costs, must be addressed to optimise integrated care.

Understanding Attitudes and Barriers

Despite the challenges in clinical management, most clinicians and support staff are optimistic about integrating HIV care into cancer treatment protocols. This positive outlook is crucial for driving successful implementation. Several barriers hinder the integration of HIV and cancer care. These include workspace limitations, workflow disruptions, staff availability, and financial burdens faced by hospitals and patients alike. There is a significant need for research to clarify service delivery pathways and address systemic barriers to integrated care approaches. Understanding these pathways can facilitate smoother integration. Over 80% of respondents agree that understanding a patient’s HIV status, antiretroviral therapy (ART) status, and ART regimen would enhance the quality of cancer care. This knowledge is essential for tailoring treatment plans.

The Intersection of HIV and Cancer

Sub-Saharan Africa faces a dual burden of high HIV prevalence and a significant incidence of HIV-related cancers, such as Kaposi sarcoma, cervical cancer, and lymphoma. The region’s healthcare systems are often under-resourced, which presents considerable challenges in screening, diagnosing, and treating these cancers effectively. Integrating HIV care into cancer centers is crucial for improving patient outcomes by streamlining care and reducing barriers from separate services. Siloed healthcare negatively affects decision-making, highlighting the need for integrated models. Organisations like the National Cancer Institute (NCI) have launched programs to research HIV-associated cancers in Africa. Initiatives such as the HIV-Associated Malignancy Research Centers and the AIDS Malignancy Consortium (AMC) aim to enhance understanding and treatment strategies. These programs are vital for addressing regional healthcare needs and advancing integrated care solutions.

Economic and Health Benefits of Integration

Integrating HIV and cancer care presents significant opportunities for enhancing both economic efficiency and patient outcomes. Healthcare systems can use resources better, reducing separate pathways and minimising effort duplication. Achieving these benefits requires investment in infrastructure, training, and financial support to overcome existing barriers

Integrating care can greatly enhance life quality for patients with HIV and cancer. Therefore, tailoring cancer treatment to HIV status and ART regimen allows for personalised, effective care. This approach improves decision-making and management, leading to better survival rates and patient satisfaction.

Furthermore, there is a pressing need for policy reforms and updated clinical practice guidelines to facilitate this integration. Training programs and infrastructure improvements can address financial and operational challenges in integrated care. Such strategic reforms are crucial for a more efficient healthcare system in regions burdened by HIV and cancer.

Reference url

Recent Posts

South Africa Health Reform: Revitalizing the Crisis-Stricken Sector

By João L. Carapinha

March 26, 2026

South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...